Y-27632 Dihydrochloride: Selective ROCK Inhibitor for Cytoskeletal and Cancer Research

Executive Summary: Y-27632 dihydrochloride is a highly selective small-molecule inhibitor of Rho-associated protein kinases ROCK1 and ROCK2, exhibiting an IC50 of approximately 140 nM for ROCK1 and a Ki of 300 nM for ROCK2, with >200-fold selectivity over other kinases (APExBIO, product page). This compound disrupts Rho-mediated stress fiber formation, modulates cell cycle progression, and inhibits cytokinesis in vitro (APExBIO). Y-27632 A3008 is widely used to enhance stem cell viability and suppress tumor invasion in preclinical models (APExBIO; Chandra et al., 2023). It is soluble at ≥111.2 mg/mL in DMSO, ≥52.9 mg/mL in water, and ≥17.57 mg/mL in ethanol at 25°C (APExBIO). The compound is supplied by APExBIO and serves as a reference standard for Rho/ROCK pathway modulation studies.

Biological Rationale

Rho-associated protein kinases (ROCK1 and ROCK2) are serine/threonine kinases central to cytoskeletal dynamics, cell motility, proliferation, and apoptosis. Dysregulation of ROCK signaling is implicated in cancer, fibrosis, neurodegeneration, and stem cell biology (Amadacycline.com, 2023). Y-27632 dihydrochloride enables precise experimental manipulation of the Rho/ROCK pathway, facilitating studies on cellular architecture and disease mechanisms (APExBIO). This article extends the discussion in Amadacycline.com by providing updated quantitative selectivity data and workflow integration parameters.

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride is a cell-permeable ROCK inhibitor that binds the catalytic domain of ROCK1 and ROCK2, blocking their kinase activity. The compound exhibits an IC50 of 140 nM for ROCK1 and a Ki of 300 nM for ROCK2, demonstrating >200-fold selectivity over kinases such as PKC, cAMP-dependent protein kinase, MLCK, and PAK (APExBIO). By inhibiting ROCK signaling, Y-27632 prevents phosphorylation of downstream effectors, reduces actin stress fiber formation, and impedes cell contractility. This leads to alterations in cell morphology, decreased motility, and interference with cytokinesis. Y-27632 also modulates the G1/S cell cycle checkpoint and enhances stem cell survival in vitro (Acridine-Orange.com, 2023). This review updates the mechanistic context compared to Acridine-Orange.com by including current selectivity figures and solubility parameters.

Evidence & Benchmarks

• Y-27632 dihydrochloride inhibits ROCK1 kinase activity with an IC50 of 140 nM in cell-free assays (APExBIO, product page).
• It exhibits a Ki of 300 nM for ROCK2, with >200-fold selectivity over PKC, PKA, MLCK, and PAK, as measured by enzymatic profiling (APExBIO).
• Y-27632 reduces Rho-mediated stress fiber formation in fibroblasts within 30 minutes at 10 μM, as visualized by phalloidin staining (APExBIO).
• In prostatic smooth muscle cell cultures, Y-27632 inhibits proliferation in a concentration-dependent manner, with maximal effect at 30 μM over 48 hours (Chandra et al., 2023).
• In mouse xenograft models, Y-27632 reduces tumor invasion and metastasis when administered at 30 mg/kg/day intraperitoneally for 14 days (Chandra et al., 2023).
• Y-27632 is soluble at ≥111.2 mg/mL in DMSO at 25°C, with enhanced dissolution upon warming to 37°C or ultrasonication (APExBIO).
• Stock solutions are stable at -20°C for several months but degrade rapidly at room temperature (APExBIO).
• Y-27632 enhances survival and proliferation of human pluripotent stem cells when added at 10 μM during passaging (Labpe.com, 2023).

Applications, Limits & Misconceptions

Y-27632 dihydrochloride is used extensively in cancer biology, stem cell research, and cytoskeletal studies. Its selectivity enables targeted dissection of Rho/ROCK signaling without major off-target effects. However, its utility is limited in certain cell types or in contexts where Rho/ROCK-independent pathways are dominant. This article clarifies misconceptions present in LHRH-Human-Acetate-Salt.com by specifying the conditions where Y-27632 is functionally ineffective or suboptimal.

Common Pitfalls or Misconceptions

• Y-27632 is not effective against non-ROCK kinases at standard concentrations (≤30 μM); off-target inhibition is minimal only above 100 μM.
• Long-term storage of Y-27632 in solution at room temperature leads to rapid degradation; always store desiccated at ≤4°C.
• Y-27632 does not reverse established fibrosis or neurodegeneration in vivo; it is best suited for acute pathway modulation.
• Cellular effects in primary neurons or immune cells may require higher concentrations or alternative inhibitors.
• In vivo dosing above 30 mg/kg/day can induce off-target toxicity in some mouse strains.

Workflow Integration & Parameters

Y-27632 dihydrochloride (APExBIO A3008) is typically supplied as a solid and should be stored desiccated at 4°C or below. For in vitro use, dissolve in DMSO at ≥111.2 mg/mL, warming to 37°C or brief ultrasonication if necessary. For aqueous applications, use water at ≥52.9 mg/mL. Prepare fresh working solutions and avoid repeated freeze-thaw cycles. For cell-based assays, 10 μM is standard for cytoskeletal studies or stem cell passaging; concentrations up to 30 μM can be used for proliferation or migration assays. For in vivo studies, dosing regimens of 10–30 mg/kg/day have been validated in mouse xenograft models (Chandra et al., 2023). For detailed guidance, refer to the Y-27632 dihydrochloride product page.

Conclusion & Outlook

Y-27632 dihydrochloride remains a gold-standard tool for selective ROCK pathway inhibition in cytoskeletal, stem cell, and cancer research. Its high specificity, robust solubility, and well-characterized benchmarks underpin its reliability in experimental design. Ongoing studies continue to refine its applications, especially in the context of disease modeling and regenerative medicine. For advanced insights and recent protocols, see Trametinib.net, which this article updates by including latest solubility specifications and in vivo limits.